Neurocrine Biosciences
$140.71Change from previous close: −0.80%Absolute change: −$1.13
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $14.3B
- Enterprise value
- $14.37B
- P/E (trailing 12 months)
- 20.8
- Forward P/E
- 11.8
- PEG
- 0.28
- Price/book
- 3.87
- Price/sales
- 4.24
- EV/EBITDA
- 15.7
- EV/revenue
- 4.26
Profitability and growth
- Gross margin
- 64.5%
- Operating margin
- 22.2%
- Net margin
- 20.9%
- ROE
- 22.1%
- ROA
- 11.7%
- Revenue growth (year over year)
- 39.5%
- Earnings growth (year over year)
- 31.1%
Financial health
- Total cash
- $389.8M
- Total debt
- $461.6M
- Debt/equity
- 0.12
- Current ratio
- 1.87
- Quick ratio
- 1.46
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- December 29, 1995
Analysts and estimates
- Average price target
- $207.81
- Median price target
- $214.00
- High price target
- $253.00
- Low price target
- $164.00
- Analysts with a price target
- 29
- Consensus
- Strong buy
- Forward EPS
- $11.88
- EPS estimate, current year
- $10.23
Shares and trading
- Beta
- 0.38
- Average volume
- 1.26M
- Shares outstanding
- 101.65M
- Float
- 100.37M
- Institutional ownership
- 102.8%
- Insider ownership
- 1.1%
- Short interest (% of float)
- 6.3%
- Short ratio (days)
- 4.85